![Seung Suh Hong](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Seung Suh Hong
Directeur/Membre du Conseil chez
OCULAR THERAPEUTIX, INC.
Fortune : 497 823 $ au 31/07/2026
Profil
Seung Suh Hong is Vice Chairman at Novalgen Ltd. since 2021 and Independent Director at Ocular Therapeutix, Inc. since 2019.
Former roles include Chief Executive Officer at Rophibio, Inc. from 2023 to 2024, Vice Chairman at Novelgen Co. Ltd (South Korea) from 2020 to 2023, President & Chief Operating Officer at Cellemedy Co., Ltd. from 2021 to 2023, President at Celltrion Healthcare Japan KK from 2016 to 2019, President & Chief Executive Officer at Celltrion Healthcare Co., Ltd. from 2014 to 2015.
Education includes undergraduate, graduate, and doctorate degrees from Seoul National University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/06/2026 | 60 933 ( 0,03% ) | 497 823 $ | 31/07/2026 |
Postes actifs de Seung Suh Hong
| Sociétés | Poste | Début |
|---|---|---|
| OCULAR THERAPEUTIX, INC. | Directeur/Membre du Conseil | 11/06/2019 |
Novalgen Ltd.
 Novalgen Ltd. BiotechnologyHealth Technology Operates as immuno oncology company | Directeur/Membre du Conseil | 01/01/2021 |
Anciens postes connus de Seung Suh Hong
| Sociétés | Poste | Fin |
|---|---|---|
Novelgen Co. Ltd(South Korea) | Directeur/Membre du Conseil | 01/03/2023 |
Cellemedy Co., Ltd.
 Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Develops next-generation cancer treatments to improve the health of people suffering from cancer | President | 01/02/2023 |
Celltrion Healthcare Japan KK | President | 02/01/2019 |
| CELLTRION HEALTHCARE CO., LTD. | Directeur Général | 01/12/2015 |
Formation de Seung Suh Hong
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
51
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
Ocular Therapeutix, Inc.
 Ocular Therapeutix, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for retinal diseases & conditions of the eye | Health Technology |
Seoul National University
 Seoul National University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Celltrion Healthcare Co., Ltd.
 Celltrion Healthcare Co., Ltd. BiotechnologyHealth Technology Develops and sells monoclonal antibody biosimilars for the treatment of cancer | Health Technology |
Celltrion Healthcare Japan KK | |
Novalgen Ltd.
Novalgen Ltd. BiotechnologyHealth Technology Operates as immuno oncology company | Health Technology |
Cellemedy Co., Ltd.
Cellemedy Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Develops next-generation cancer treatments to improve the health of people suffering from cancer | Commercial Services |
Novelgen Co. Ltd(South Korea) |
